In accordance with preclinical observations reporting an increased susceptibility to venetoclax in IDH1/2-mutated AML cells, the subgroup of AML patients harboring IDH1/2 mutations has shown high rates of durable remissions in clinical studies associating HMAs with venetoclax. This evidence concerns the gene IDH1 and acute myeloid leukemia.